LSP BioVentures
VC Fund
Cambridge, United States
LSP BioVentures is a venture capital fund focused on opportunities in the life science arena. Based in Cambridge (MA) in the USA; the fund’s management combines the strength of its parent company, Life Sciences Partners Venture Capital firm in Europe and a dedicated team of experts in the USA.
- Total investments:
- 26
- Last investment:
- Lead investor:
- 46%
- Fund size:
- $1.2B
- Last fund:
Last updated:
For AI agents: llms.txt
Industries LSP BioVentures invests in
Stages LSP BioVentures invests in
Countries LSP BioVentures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $5.3M–$194M
- Series B
- $5.3M–$45M
- Series C
- $8M–$100M
Investment Focus
Industry
- Biotechnology 22 (85%)
- Health Care 15 (58%)
- Therapeutics 8 (31%)
- Medical 7 (27%)
- Pharmaceutical 5 (19%)
Stage
- Series A 9 (35%)
- Series B 8 (31%)
- Series C 6 (23%)
- Funding Round 2 (8%)
- Series D 1 (4%)
Country
- United States 9 (35%)
- Germany 5 (19%)
- United Kingdom 3 (12%)
- The Netherlands 3 (12%)
- Belgium 2 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Martijn Kleijwegt
Managing Partner
|
Managing Partner | Total investments: 9 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
HotSpot Therapeutics
|
HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts. | $100M / Series C / Nov 29, 2021 | |
Evommune
|
Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. Evommune creates novel strategies to treat inflammatory disorders by developing treatments that address symptoms while also halting disease progression. Evommune's pipeline contains initiatives aimed atcombating highly prevalent inflammatory illnesses. Its mission is to drive real advancements for patients suffering from these diseases, with all of its programs designed to produce best-in-class profiles. | $83M / Series A / Sep 09, 2021 | |
Muna Therapeutics
|
Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's. | $73M / Series A / Jul 09, 2021 | |
Innovative Molecules
|
Innovative Molecules develops drugs designed to treat Herpes simplex-induced diseases. | $24.4M / Series A / Jun 09, 2021 | |
New Amsterdam Pharma
|
NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. | $194.4M / Series A / Jan 14, 2021 | |
Lumeon
|
Lumeon is a digital health company that has defined the market for Care Pathway Management (CPM). From scheduling and revenue management to clinical reporting and aftercare, by looking across the end-to end care pathway, Lumeon addresses the system, and not just the symptom, behind healthcare transformation. Lumeon's customers number amongEurope’s fastest growing and most innovative healthcare providers including BUPA, Nuffield Health, Alliance Medical, HCA, Optegra and Newmedica. It is headquartered in London employing over 90 people. | $30M / Series D / Aug 11, 2020 | |
iSTAR Medical
|
iSTAR Medical SA was created in 2010 as a spinout of Healionics Corporation with support from Belgium's Region Wallonne government. In 2011, iSTAR expanded to its new eco-friendly R&D and Manufacturing facility in CREALYS Scientific Park near Namur, Belgium.By 2012, iSTAR received ISO 13485 and ISO 9001 Quality SystemsCertifications and achieved CE Mark approval of its first device - STARflo™ Glaucoma Implant. | $43.9M / Series C / Sep 05, 2019 | |
Imcyse
|
Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on theadministration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases. | $30.7M / Series B / Jun 18, 2019 | |
|
Lumeon
|
Lumeon is a digital health company that has defined the market for Care Pathway Management (CPM). From scheduling and revenue management to clinical reporting and aftercare, by looking across the end-to end care pathway, Lumeon addresses the system, and not just the symptom, behind healthcare transformation. Lumeon's customers number amongEurope’s fastest growing and most innovative healthcare providers including BUPA, Nuffield Health, Alliance Medical, HCA, Optegra and Newmedica. It is headquartered in London employing over 90 people. | $28M / Series C / Dec 04, 2018 | |
Aelin Therapeutics
|
Aelin Therapeutics, a privately held Belgian biotherapeutics company.Aelin Therapeutics is founded by VIB and its partner universities KU Leuven, VUB and UGent, based on the groundbreaking work of renowned structural biologists Prof Joost Schymkowitz and Prof Frederic Rousseau. The company is based on a very comprehensive preclinical Proof ofConcept data package illustrating different applications of the technology such as in bacteria and cancer cells, but also in fungi, viruses and plant cells, with publications in high impact journals including Science. The Pept-in technology allows for the rational design of novel biotherapeutics and differentiates itself from any other therapeutic modality through its unique mode of action, its designability and intracellular target space out of reach for typical small molecule or antibody approaches. | $29.6M / Series A / Dec 11, 2017 | |
| See all 26 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does LSP BioVentures invest in?
LSP BioVentures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 26 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is LSP BioVentures's check size?
LSP BioVentures typically joins rounds of $5.3M–$194M at Series A, $5.3M–$45M at Series B and $8M–$100M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds LSP BioVentures participates in.
How do I contact LSP BioVentures?
Public channels for LSP BioVentures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at LSP BioVentures?
The team at LSP BioVentures includes Martijn Kleijwegt (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
